USANA Health Sciences, Inc. (NYSE:USNA – Get Free Report) insider David Mulham Mulham sold 3,234 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the transaction, the insider now owns 12,775 shares in the company, valued at approximately $421,319.50. This represents a 20.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
USANA Health Sciences Trading Down 0.2 %
Shares of USNA stock traded down $0.06 during midday trading on Tuesday, reaching $33.03. 81,747 shares of the stock were exchanged, compared to its average volume of 174,238. USANA Health Sciences, Inc. has a 1 year low of $27.71 and a 1 year high of $50.32. The firm has a market cap of $629.46 million, a PE ratio of 11.67, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98. The company’s 50 day moving average is $32.96 and its two-hundred day moving average is $36.18.
USANA Health Sciences (NYSE:USNA – Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. As a group, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
USNA has been the topic of several research analyst reports. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Finally, Sidoti cut shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th.
Get Our Latest Research Report on USNA
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
See Also
- Five stocks we like better than USANA Health Sciences
- 3 Fintech Stocks With Good 2021 Prospects
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What Does Downgrade Mean in Investing?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- How to Calculate Return on Investment (ROI)
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.